Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPI-504 versus placebo in previously treated unresectable or metastatic GIST
2008-002396-28Phase 3Terminated
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastrointestinal stromal tumor (GIST) comparing Retaspimycin hydrochloride plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Progression-free survival. Started Nov 2008; status: terminated.
02
Drugs
retaspimycin
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2008-002396-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002396-28.